Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A second phase Ib clinical trial in patients with paroxysmal nocturnal hemoglobinuria (PNH) to assess the safety, preliminary efficacy and pharmacokinetics of subcutaneously administered APL-2 alone or in combination with eculizumab

Next Previous
X
Search
Trial Profile

A second phase Ib clinical trial in patients with paroxysmal nocturnal hemoglobinuria (PNH) to assess the safety, preliminary efficacy and pharmacokinetics of subcutaneously administered APL-2 alone or in combination with eculizumab

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegcetacoplan (Primary) ; Eculizumab
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions

    • Most Recent Events

    • 19 Mar 2018 According to an Apellis media release, updates from this study are anticipated in the first half of 2018.
    • 21 Nov 2016 Data from this and another phase Ib trial will be presented at the International PNH Interest Group (IPIG) Annual Scientific Assembly 2016, according to an Apellis Pharmaceuticals media release.
    • 28 Jun 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top